Skip to main content
Terug
Watch Compare

Pharma-Bio Serv, Inc.

Datakwaliteit: 100%
PBSV
OTC Services Engineering & Management Services
€ 0,50
€ 0,00 (0,00%)
Marktkapitalisatie: 11,45 M
Prijs
€ 0,50
Marktkapitalisatie
11,45 M
Dagbereik
€ 0,49 — € 0,49
52-Weeksbereik
€ 0,40 — € 1,36
Volume
7.501
Openen € 0,49
50D / 200D Gem.
€ 0,53
5,30% below
50D / 200D Gem.
€ 0,57
12,05% below

Quick Summary

Belangrijkste Punten

Revenue declined -18,21% annually over 5 years
Negative free cash flow of -184.594,0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12,87%
Capital efficient — spends only 0,10% of revenue on capex

Groei

Revenue Growth (5Y)
-18,21%
Onder sectorgemiddelde (3,99%)
Revenue (1Y)-5,34%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-0,69%
Boven sectorgemiddelde (-15,95%)
ROIC-4,56%
Net Margin-0,86%
Op. Margin-7,25%

Veiligheid

Debt / Equity
N/A
Current Ratio4,03
Interest CoverageN/A

Waardering

PE (TTM)
-150,39
Onder sectorgemiddelde (-1,17)
P/B Ratio1,12
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (502 peers)
Metriek Aandeel Sector Mediaan
P/E -150,4 -1,2
P/B 1,1 1,4
ROE % -0,7 -16,0
Net Margin % -0,9 -19,4
Rev Growth 5Y % -18,2 4,0
D/E — 0,4

All Fundamental Metrics
Growth
Revenue Growth (1Y) -5,34% Revenue Growth (3Y) -27,19%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -18,21% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 8,82 M Net Income (TTM) -76.139,0
ROE -0,69% ROA -0,56%
Gross Margin 32,46% Operating Margin -7,25%
Net Margin -0,86% Free Cash Flow (TTM) -184.594,0
ROIC -4,56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,03
Interest Coverage N/A Asset Turnover 0,65
Working Capital 10,01 M Tangible Book Value 10,24 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -150,39 Forward P/E N/A
P/B Ratio 1,12 P/S Ratio 1,30
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1,61%
Market Cap 11,45 M Enterprise Value 11,45 M
Per Share
EPS (Diluted TTM) 0,00 Revenue / Share 0,39
FCF / Share -0,01 OCF / Share -0,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,10% FCF Conversion 242,44%
SBC-Adj. FCF -223.893 Growth Momentum 12,87

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9,00 M 9,51 M 16,98 M 19,40 M 20,12 M
Net Income -100.463,0 -777.619,0 1,31 M 1,01 M -2,09 M
EPS (Diluted) 0,00 -0,03 — — —
Gross Profit 2,91 M 2,52 M 5,07 M 4,88 M 5,36 M
Operating Income -637.662,0 -1,29 M 1,12 M 1,17 M -3,85 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses 3,55 M 3,80 M 3,95 M 3,71 M 9,21 M
D&A 59.866,0 23.311,0 48.086,0 51.107,0 72.728,0
Interest Expense — — — — —
Income Tax 6.203,0 22.171,0 377.307,0 181.679,0 213.246,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 13,65 M 16,29 M 19,90 M 20,65 M 23,92 M
Total Liabilities 1,74 M 2,58 M 3,78 M 4,09 M 5,01 M
Shareholders' Equity 11,91 M 13,72 M 16,13 M 16,56 M 18,91 M
Total Debt — — — — —
Cash & Equivalents — — — 14,46 M 17,47 M
Current Assets 13,39 M 15,70 M 19,40 M 19,94 M 22,82 M
Current Liabilities 1,74 M 1,89 M 2,15 M 2,11 M 2,65 M